Navigation Links
DrugRisks Adds Update from First Actos Trial of Patient Alleging Bladder Cancer
Date:3/27/2013

Los Angeles, CA (PRWEB) March 27, 2013

The drug safety advocates at DrugRisks.com are announcing updated legal news on the site for patients who have taken the diabetes drug Actos. The first trial began this month for a retired man who alleges he developed bladder cancer after taking the medication.

DrugRisks was created to provide those taking popular prescription drugs like Actos with the latest safety alerts, recalls, studies and legal news. Visitors can determine if other patients are experiencing similar side effects and decide if they need legal advice.

Health experts with the FDA and European Medicines Agency* have warned that use of Actos for extended amounts of time may be linked to an increased risk of bladder cancer. Regulators in France and Germany have also banned its use**.

In the United States, as many as 3,000 patients have filed an Actos lawsuit against drug maker Takeda Pharmaceuticals over allegations of bladder cancer***. Over 1,200 of these have been consolidated in a special multi-district federal court in Louisiana, while others are pending in California.

Now, DrugRisks has learned that the first Actos lawsuit trial began this month in California for a retired man who alleges the drug has left him terminally ill from bladder cancer***. At the trial, a former pharmacologist for Takeda testified that the company was more concerned with continued sales of the drug rather than the safety of patients***.

Lawyers continue to help those diagnosed with bladder cancer after taking Actos file claims. Anyone affected is urged to contact the DrugRisks Center or speak with a lawyer about their legal rights as soon as possible.

Due to the specialized nature of drug injury litigation against large pharmaceutical companies, DrugRisks only recommends lawyers and law firms who have already handled Actos lawsuits.

Visit http://www.DrugRisks.com today for more information on Actos bladder cancer research, side effects and litigation news, or to speak with a lawyer.

*fda.gov/ForConsumers/ConsumerUpdates/ucm263431.htm#Actos; ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/public_health_alerts/2011/07/hu an_pha_detail_000033.jsp&mid=WC0b01ac058001d126
**cbsnews.com/8301-504763_162-20070492-10391704.html
***bloomberg.com/news/2013-03-05/takeda-put-actos-sales-ahead-of-user-safety-witness-says.html; Cooper v. Takeda Pharmaceuticals America Inc., CGC-12-518535, California Superior Court (Los Angeles).

Read the full story at http://www.prweb.com/releases/actos-bladder-cancer/actos-lawsuit/prweb10573586.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Frozen Food Production in the US Industry Market Research Report from IBISWorld has Been Updated
2. Fitment Guide Update for the 2012 Land Rover Range Rover Evoque, Made by SizeItUp
3. Hip Safety Center Update: Patients Ask to Send Stryker Hip Lawsuits to Federal Court
4. Drug Safety Center Update: Employee Alleges Actos Maker Valued Sales Over Safety
5. DrugRisk Update: Evidence Submitted in Actos Lawsuit Suggests Drug Maker Knew of Cancer Risks
6. Update: Number of Stryker Rejuvenate Hip Recall Lawsuits Growing in New Jersey Multicounty Litigation, Announces Wright & Schulte LLC
7. Harmonic Software Systems Announces an Updated Version of Their DigitalMeds iPhone App
8. DrugRisk Update: Bayer Discloses $500 Million Remaining for Yaz Lawsuits
9. Updated stereo EEG workflow simplifies planning of epilepsy surgery
10. American Emu Association Updates Quality Regulations in Response to Fraudulent Oils in Market
11. Tylenol Liver Failure Allegation Lawsuits Update: Resource4thePeople Reports Hearing to Consolidate Federal Cases Is Scheduled
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... 2017 , ... Much attention has been paid to the problem of men ... painkillers has fallen short. From 1999 until 2010, fatal overdoses from prescription pain medications ... in male populations.(1) , The proportion of women using illicit drugs is also increasing ...
(Date:2/27/2017)... ... ... Orange County dentist, Dr. A. Rassouli, comments on the new ... bacteria in plaque infect the gums and other tissues supporting the teeth. Treatment typically ... SRP, and can include surgical therapies if the condition has led to significant damage. ...
(Date:2/27/2017)... POUGHKEEPSIE, N. Y. (PRWEB) , ... February 27, 2017 , ... ... Society ( ILADS ) has disclosed that despite scientific studies, the Center for Disease ... of chronic Lyme disease . Kenneth B. Liegner, M.D. has compiled into ...
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon ... proud to announce a new informational post on robotic hair transplantation. San Francisco ... (FUE) hair transplant and Follicular Unit Transplantation (FUT) can sound similar. Either treatment ...
(Date:2/26/2017)... (PRWEB) , ... February 25, 2017 , ... The February ... Jong-un, heightened awareness and concern over nerve agents and the deadly use of chemical ... human nervous system and how even small doses can be lethal. , Jay Jagannathan, ...
Breaking Medicine News(10 mins):
(Date:2/28/2017)... Fourth-quarter 2016 revenues of $1,242 million brings ... of guidance Company reports ... associated with the write-down of goodwill and intangible assets ... Fourth-quarter reported $14.96 diluted (GAAP) ... $14.48 diluted (GAAP) loss per share from continuing operations ...
(Date:2/27/2017)... Halyard Health, Inc. (NYSE: HYH ) ... its 2017 outlook and related key planning assumptions. Executive Summary ... a 2 percent increase compared to the prior year. ... $10 million compared to net income of $15 million in ... was $24 million compared to adjusted net income of $27 ...
(Date:2/27/2017)... 27, 2017  Interpace Diagnostics Group, Inc. (NASDAQ: IDXG), ... molecular diagnostic tests and pathology services, announced today the ... upcoming United States and Canadian ... 2017 in San Antonio, Texas . ... data from the Company,s extensive experience in molecular thyroid ...
Breaking Medicine Technology: